Autophagy inducers are therapeutic compounds that enhance cellular autophagy—the evolutionarily conserved process by which cells degrade and recycle misfolded proteins, damaged organelles, and protein aggregates. This therapeutic strategy directly addresses the accumulation of toxic protein aggregates that characterize neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). [1]
Autophagy (specifically macroautophagy) involves the formation of double-membrane autophagosomes that engulf cellular debris and fuse with lysosomes for degradation. The autophagy-lysosomal pathway is crucial for neuronal health because post-mitotic neurons cannot dilute toxic proteins through cell division. [2]
Compromised autophagy is a hallmark of neurodegeneration:
Multiple molecular pathways regulate autophagy: [3]
| Type | Examples | Advantages | Limitations |
|---|---|---|---|
| mTOR inhibitors | Rapamycin, Everolimus | Well-characterized, potent | Immunosuppression, metabolic effects |
| mTOR-independent | Trehalose, Carbamazepine | Safer profile | Weaker induction |
| AMPK activators | Metformin, Resveratrol | Multi-target benefits | Less brain penetration |
| TFEB activators | Genistein, Daidzein | Direct lysosomal biogenesis | Preclinical stage |
Autophagy induction addresses multiple AD pathologies: [4]
Clinical evidence: Rapamycin (Sirolimus) has shown cognitive benefit in small AD trials, with Phase II studies ongoing (NCT04629495). Everolimus (NCT02550349) demonstrated cognitive benefit in moderate AD.
Autophagy enhancement is particularly relevant to 4R-tauopathies including CBS and PSP, where:
Rapamycin directly addresses mTORC1 hyperactivation and can clear 4R-tau aggregates via autophagy. The geroscience dosing (5-6 mg weekly) is well-tolerated with no immunosuppression at low intermittent doses.
Trehalose shows particular promise for CBS/PSP due to its mTOR-independent mechanism:
Clinical trials: NCT04833638 (CBD Phase 1) is evaluating trehalose specifically in corticobasal degeneration, making it directly relevant to this patient's differential diagnosis.
Rapamycin (Sirolimus) addresses the mTORC1 hyperactivation documented in PSP:
Off-label consideration: Rapamycin is FDA-approved for transplant rejection. Off-label use for neurodegeneration requires monitoring lipids, blood counts, and infection signs.
PD particularly benefits from autophagy enhancement due to α-synuclein pathology: [5]
Clinical evidence: Carbamazepine (NCT04643145) and trehalose (NCT02939460) have completed Phase I trials showing safety.
HD is uniquely responsive to autophagy induction: [6]
Clinical evidence: Laquinimod (NCT02221116) and trehalose (NCT04577370) have completed HD trials.
ALS involves TDP-43 and SOD1 aggregates amenable to autophagy: [7]
Clinical evidence: Rapamycin has been explored in ALS (NCT02444737) with mixed results.
| Drug | Mechanism | Disease | Clinical Stage | Key Trials |
|---|---|---|---|---|
| Rapamycin (Sirolimus) | mTORC1 inhibitor | AD/PD/PSP/CBS | Phase II | NCT04629495, NCT05915091 |
| Everolimus | mTORC1 inhibitor | AD | Phase II | NCT02550349 |
| Trehalose | mTOR-independent | HD/PD/ALS | Phase II | NCT05119283, NCT04644081, NCT04534478 |
| Metformin | AMPK activator | AD/PD | Phase II | NCT0409866 |
| Lithium | mTOR-independent + GSK-3β | HD/ALS | Phase II | NCT00751842 |
| Resveratrol | AMPK/SIRT1 activator | AD/PD | Phase II | NCT00245271 |
| Carbamazepine | mTOR-independent | PD | Phase I | NCT04643145 |
| Nicotinamide | SIRT1 activator | HD | Phase I | NCT0225549 |
| Genistein | TFEB activator | AD/PD | Preclinical | — |
| Laquinimod | Immunomodulator | HD | Phase II | NCT02221116 |
| Trial ID | Agent | Indication | Phase | Status | Key Endpoints |
|---|---|---|---|---|---|
| NCT04629495 | Rapamycin | Alzheimer's | Phase II | Recruiting | Cognitive, CSF biomarkers |
| NCT05915091 | Rapamycin | Aging | Phase II | Recruiting | Healthspan metrics |
| NCT05119283 | Trehalose | ALS | Phase II | Recruiting | Safety, ALSFRS-R |
| NCT04644081 | Trehalose | Alzheimer's | Phase II | Active, not recruiting | Cognitive, brain volume |
| NCT04833638 | Trehalose | CBD | Phase I | Recruiting | Safety, pharmacokinetics |
Trehalose (NCT04833638): This is the most directly relevant trial for this patient's differential. CBD (corticobasal degeneration) shares pathological features with PSP as a 4R-tauopathy. Results from this trial will inform broader application to 4R-tauopathies.
Rapamycin: No ongoing PSP-specific trials. Off-label use is supported by the strong mechanistic rationale (mTORC1 hyperactivation in PSP) and safety data from other indications.
| Trial ID | Agent | Indication | Phase | Key Findings |
|---|---|---|---|---|
| NCT04534478 | Trehalose | Parkinson's | Phase I/II | Completed, safety established |
| NCT04200911 | Rapamycin | ALS | Phase II | Completed, mixed results |
| NCT02550349 | Everolimus | AD | Phase II | Cognitive benefit observed |
Autophagy induction offers disease-modifying potential: [8]
Current research focuses on: [9]
Autophagy induction has important considerations:
Rubinsztein DC, et al. Autophagy and misfolded protein clearance in neurodegenerative diseases. Nature Reviews Drug Discovery. 2012. ↩︎
Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine. 2013. ↩︎
Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nature Reviews Neurology. 2012. ↩︎
Menzies FM, et al. Autophagy induction as a therapeutic strategy for neurodegenerative diseases. Molecular Cell. 2017. ↩︎
Moors TE, et al. Therapeutic potential of autophagy-enhancing drugs in neurodegenerative proteinopathies. Nature Reviews Drug Discovery. 2020. ↩︎
Sarkar S, et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteins. Journal of Cell Biology. 2007. ↩︎
Chen S, et al. Autophagy and ALS: Mechanisms and therapeutic targets. Trends in Neurosciences. 2023. ↩︎
Fleming A, et al. The different autophagy pathways in neurodegeneration. Journal of Molecular Biology. 2020. ↩︎
Song JX, et al. Trehalose, an autophagy inducer, ameliorates alpha-synuclein pathology. Autophagy. 2019. ↩︎